MAY 11, 2017
Shire has continued to pull strong profits following the launch of their dry eye drug lifitegrast (Xiidra) in August 2016.
The company’s first-quarter 2017 report shows $3.57 billion in revenue, up 109% from the same period last year. Their ophthalmology franchise contributed $38.6 million in total product sales and acquired 22% of the U.S. market as of March 2017. At the end of 2016, lifitegrast had already captured 19% of market share.
Filing for approval of lifitegrast in Europe is scheduled for the third quarter of 2017.